Table 1 Characteristics of patients at the time of inclusion in the study.

From: HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy

Characteristic

Study group

p-value

HIV-monoinfected patients

HCV/HIV-coinfected patients

n

25

25

–

Age (years)

48 [41–54]

44 [38–47]

0.106

Male (%)

88

100

0.074

HIV Viral load (copies/mL)

 < 50

 < 50

NA

CD4 counts (cells/µL)

816 [604–991]

735 [577–902]

0.313

Time since HIV diagnosis (years)

9 [6–13]

7 [2–10]

0.072

Time on cART (years)

5 [3–7]

4 [2–9]

0.632

Type of ART regimens

0,001

NRTI + NNRTI

36

0

NRTI + INI

56

100

NRTI + PI

8

0

Risk group for HIV infection

0.312

Sexual transmission (%)

100

96

Parenteral transmission (%)

0

4

Prevalence of comorbidities (%)

44

40

0.774

Type of comorbidities (%)

AIDS related events

8

20

0.221

Cardiovascular

8

20

0.221

Metabolic

16

8

0.384

Renal

0

4

0.312

Osteoporosis

20

4

0.082

Cancer

0

4

0.312

  1. Data are expressed as median [IQR], except sex and risk group for HIV infection, expressed as %; p-value: comparison between HIV-monoinfected and HCV/HIV-coinfected groups (U-Mann–Whitney test), except sex, type of ART regimens, risk group for HIV infection and comorbidities (evaluated with χ2 test).
  2. NA not apply, NRTI nucleoside analog reverse-transcriptase inhibitor, NNRTI non-nucleoside reverse-transcriptase inhibitor, INI integrase inhibitor, PI protease inhibitor.
Back to article page